Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.68 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.64 |
| ▸ | MAPT | P10636 | 5/20 | 0.61 |
| ▸ | LMNA | P02545 | 4/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.61 |
| ▸ | MEN1 | O00255 | 6/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.57 |
| ▸ | NPC1 | O15118 | 4/20 | 0.57 |
| ▸ | RAB9A | P51151 | 4/20 | 0.57 |
| ▸ | POLB | P06746 | 2/20 | 0.57 |
| ▸ | GAA | P10253 | 2/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.57 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.57 |
| ▸ | CASP3 | P42574 | 1/20 | 0.57 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.57 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.57 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.57 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.57 |
| ▸ | HTT | P42858 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL5119113 | 0.98 | CYP1A2 (0.66) | CYP1A2KDM4EMAPTLMNAALDH1A1 | |
| SCHEMBL10458447 | 0.87 | KDM4E (0.72) | CYP1A2KDM4EMAPTLMNAALDH1A1 | |
| SCHEMBL9168941 | 0.82 | MAPT (0.59) | CYP1A2KDM4EMAPTLMNAALDH1A1 | |
| SCHEMBL19006812 | 0.82 | KDM4E (0.66) | KDM4EMAPTLMNAALDH1A1MEN1 | |
| SCHEMBL11449284 | 0.82 | CYP1A2 (0.65) | CYP1A2KDM4EMAPTLMNAALDH1A1 | |
| SCHEMBL2175829 | 0.81 | CYP1A2 (0.75) | CYP1A2KDM4EMAPTLMNAALDH1A1 | |
| SCHEMBL29537172 | 0.81 | CYP1A2 (0.75) | CYP1A2KDM4EMAPTLMNAALDH1A1 | |
| Hydrochloric Acid SCHEMBL9630506 | 0.80 | KDM4E (0.64) | KDM4EMAPTLMNAALDH1A1MEN1 | |
| SCHEMBL8830517 | 0.80 | SMN1; SMN2 (0.73) | CYP1A2KDM4EMAPTLMNAALDH1A1 | |
| SCHEMBL8421117 | 0.80 | CYP1A2 (0.62) | CYP1A2KDM4EMAPTLMNAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250243161-A1 | DELIVERY OF THERAPEUTIC ALKALOID COMPOUNDS | SENSORIUM THERAPEUTICS, INC. | 2025-07-31 | — | — | US | disclosed |
| US-12269800-B2 | Delivery of therapeutic alkaloid compounds | SENSORIUM THERAPEUTICS, INC. (US) | 2025-04-08 | — | — | US | disclosed |
| US-20250051277-A1 | DELIVERY OF THERAPEUTIC ALKALOID COMPOUNDS | SENSORIUM THERAPEUTICS, INC. | 2025-02-13 | — | — | US | disclosed |
| US-20240246910-A1 | DELIVERY OF THERAPEUTIC ALKALOID COMPOUNDS | SENSORIUM THERAPEUTICS, INC. | 2024-07-25 | — | — | US | disclosed |
| US-11999694-B2 | Delivery of therapeutic alkaloid compounds | SENSORIUM THERAPEUTICS, INC. (US) | 2024-06-04 | — | — | US | disclosed |
| US-20230159455-A1 | DELIVERY OF THERAPEUTIC ALKALOID COMPOUNDS | SENSORIUM THERAPEUTICS, INC. | 2023-05-25 | — | — | US | disclosed |
| US-20230159455-A1 | DELIVERY OF THERAPEUTIC ALKALOID COMPOUNDS | SENSORIUM THERAPEUTICS, INC. | 2023-05-25 | — | — | US | disclosed |
| US-20230159455-A1 | DELIVERY OF THERAPEUTIC ALKALOID COMPOUNDS | SENSORIUM THERAPEUTICS, INC. | 2023-05-25 | — | — | US | disclosed |
| WO-2023076586-A1 | DELIVERY OF THERAPEUTIC ALKALOID COMPOUNDS | SENSORIUM THERAPEUTICS, INC. (US) | 2023-05-04 | — | — | WO | disclosed |
| WO-2021127459-A1 | GPR139 RECEPTOR MODULATORS | BLACKTHORN THERAPEUTICS, INC. (US) | 2021-06-24 | — | — | WO | disclosed |
| WO-2021127459-A1 | GPR139 RECEPTOR MODULATORS | BLACKTHORN THERAPEUTICS, INC. (US) | 2021-06-24 | — | — | WO | disclosed |
| EP-0566445-B1 | Derivatives of indane 1,3-dione and indane-1,2,3-trione, processes for their preparation and their application in therapy | INNOTHERA LAB SA (FR) | 1996-02-07 | — | — | EP | disclosed |
| EP-0474817-B1 | BICYCLO [3.3.0]OCTANE DERIVATIVES, PROCESS FOR PRODUCING THEM AND THEIR PHARMACEUTICAL USE | SCHERING AG (DE) | 1995-10-11 | — | — | EP | disclosed |
| EP-0566445-A1 | Derivatives of indane 1,3-dione and indane-1,2,3-trione, processes for their preparation and their application in therapy | INNOTHERA (FR) | 1993-10-20 | — | — | EP | disclosed |
| WO-1993020045-A1 | INDAN-1,3-DIONE AND INDAN-1,2,3-TRIONE DERIVATIVES, PROCESSES FOR THE PREPARATION OF SAME AND THEIR APPLICATION AS THERAPEUTIC AGENTS | INNOTHERA (FR) | 1993-10-14 | — | — | WO | disclosed |
| EP-0474817-A1 | BICYCLO 3.3.)]OCTANE DERIVATIVES, PROCESS FOR PRODUCING THEM AND THEIR PHARMACEUTICAL USE. | SCHERING AG (DE) | 1992-03-18 | — | — | EP | disclosed |
| WO-1991014675-A1 | BICYCLO[3.3.)]OCTANE DERIVATIVES, PROCESS FOR PRODUCING THEM AND THEIR PHARMACEUTICAL USE | SCHERING AKTIENGESELLSCHAFT BERLIN UND BERGKAMEN (DE) | 1991-10-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250051277-A1 | DELIVERY OF THERAPEUTIC ALKALOID COMPOUNDS | PNMT, HNMT, NNMT | CYP1A2 313/4885KDM4E 2549/4885MAPT 2002/4885 |
| US-20250243161-A1 | DELIVERY OF THERAPEUTIC ALKALOID COMPOUNDS | PNMT, HNMT, NNMT | CYP1A2 313/4885KDM4E 2549/4885MAPT 2002/4885 |
| US-20230159455-A1 | DELIVERY OF THERAPEUTIC ALKALOID COMPOUNDS | PNMT, HNMT, NNMT | CYP1A2 313/4885KDM4E 2549/4885MAPT 2002/4885 |
| US-20240246910-A1 | DELIVERY OF THERAPEUTIC ALKALOID COMPOUNDS | PNMT, HNMT, NNMT | CYP1A2 313/4885KDM4E 2549/4885MAPT 2002/4885 |
| US-12269800-B2 | Delivery of therapeutic alkaloid compounds | PNMT, HNMT, NNMT | CYP1A2 313/4885KDM4E 2549/4885MAPT 2002/4885 |
| US-11999694-B2 | Delivery of therapeutic alkaloid compounds | PNMT, HNMT, NNMT | CYP1A2 313/4885KDM4E 2549/4885MAPT 2002/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.